Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Want to cut your energy bills? Here’s how five experts are doing it 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
MALVERN, Pa., March 17, 2016 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, will release its fourth quarter and full year 2015 financial results after the market close on Wednesday, March 23, 2016.
Management will conduct a conference call at 4:30 p.m. ET that day to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors Relations” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (877) 481-7177 (domestic) or (262) 558-6167 (international), and reference conference ID 50890341 prior to the start of the call.
About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology. Aclaris Therapeutics, Inc. is based in Malvern, Pennsylvania and more information can be found by visiting the company’s website at www.aclaristx.com.
Contact: Aclaris Contact Frank Ruffo Chief Financial Officer 484-324-7933 [email protected] Investor Contact Patricia L. Bank Westwicke Partners Managing Director 415-513-1284 [email protected] Media Contact Mike Beyer Sam Brown, Inc. 312-961-2502 [email protected]
